首页> 美国卫生研究院文献>United European Gastroenterology Journal >Deprescribing medications that may increase the risk of hepatic encephalopathy: A qualitative study of patients with cirrhosis and their doctors
【2h】

Deprescribing medications that may increase the risk of hepatic encephalopathy: A qualitative study of patients with cirrhosis and their doctors

机译:贬低可能增加肝脑病风险的药物:对肝硬化患者及其医生的定性研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Multiple medications are associated with an increased risk of incident hepatic encephalopathy. Despite this known risk, medications such as opioids, benzodiazepines, gabapentin/pregabalin, and/or proton pump inhibitors are increasingly prescribed to persons with cirrhosis. Deprescribing is a promising intervention to reduce the burden of hepatic encephalopathy. Given that deprescribing has not been trialed in cirrhosis, we evaluated the barriers and facilitators to safe and successful deprescribing in cirrhosis.
机译:多种药物与入射肝脑病的风险增加有关。尽管存在这种已知的风险,但阿片类药物,苯二氮卓类药物,加巴普蛋白/普罗那萘林和/或质子泵抑制剂等药物越来越多地向肝硬化的人开展。贬低是减少肝脑病的负担的有希望的干预。鉴于剥夺剥夺症尚未在肝硬化中进行试验,我们评估了障碍和促进者在肝硬化中安全和成功贬低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号